We studied clinical and immunological effectiveness of forphenicinol, a low molecular weight immunomodulator, in nine patients with chronic respiratory tract infection. Underlying diseases were diffuse panbronchiolitis in 8 cases and bronchiectasis in one case, and as a causative organism
Pseudomonas aeruginosa was isolated in 7 cases, and GNF-GNR was in 2 cases. Forphenicinol was orally administered at the dose of 50 or 100 mg per day for 30 to 562 days (average 357 days), and 3.0 to 56.2g (average 31.8 g) totally. The results obtained were as follows.
1. Forphenicinolshowedeffectivenessin55.6%ofgcasesincludingfairresponses.
2.Neither
P.aeruginosa nor GNF-GNR was eradicated in all 9 cases after the treatment with forphenicinol.
3. Forphenicinol caused neither adverse effects nor abnormal laboratory findings.
4. From the point of immunological view, T and B lymphocyte subsets studied by rosette methods did not change significantly, but a subset of suppressor T lymphocyte detected by OKT8 monoclonal antibody showed some decrease. However, there was no significant change in NK cell activity after the treatment with forphenicinol.
Because forphenicinol shows little toxicity, is capable of beening administered for a long time and would enhance the antibody production by reducing suppressor T cells, we conclude that it is worthwhile to administer this drug for the patients with chronic respiratory infections.
View full abstract